• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GENOMIC HEALTH INC ONCOTYPEDX

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GENOMIC HEALTH INC ONCOTYPEDX Back to Search Results
Device Problem Manufacturing, Packaging or Shipping Problem (2975)
Patient Problem Breast Cancer (1759)
Event Date 09/06/2012
Event Type  malfunction  
Event Description
In (b)(6) 2012, i was diagnosed with stage 1a breast cancer (er+, pr-, her2-, ln 0/3, brca neg,) and had a unilateral mastectomy on my right breast.An oncotype dx test was performed on my tumors to determine if this early stage breast cancer needed chemotherapy to reduce my risk of recurrence.The result was an intermediate score of 21.At that time, the intermediate range went from 18 - 30, so i was considered in the "low range of intermediate." both my surgeon and oncologist discussed with me the pros and cons of chemo, but tended to side towards no chemo.I sought out other opinions - one oncologist said "get chemo, no question", another surgeon said "it was a toss-up as to the benefits vs the side effects." and another doctor wanted to draw a line down the middle, and say that 21 was closer to "low risk" so i didn't need chemo.I was also invited to fly down to (b)(6) for a consult (i didn't go.) my oncologist said it was my decision and that he would not specifically say "do chemo." i didn't go to medical school, so why am i making this decision? i found the results of this test to be very misleading and highly confusing.As this tent was created to determine my need for chemotherapy, no one was able to provide a clear answer with back up data.I then learned that the test was not fda cleared, and that the statistics that were quoted to me depended on taking tamoxifen for five years (that point was not clearly stated).How can a test with so many holes be on the market? this company needs to be held accountable for misleading patients!.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ONCOTYPEDX
Type of Device
ONCOTYPEDX
Manufacturer (Section D)
GENOMIC HEALTH INC
MDR Report Key5406487
MDR Text Key37622912
Report NumberMW5059937
Device Sequence Number0
Product Code OQS
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Patient
Type of Report Initial
Report Date 01/29/2016
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this a Product Problem Report? Yes
Device Operator No Information
Initial Date Manufacturer Received Not provided
Initial Date FDA Received01/29/2016
Type of Device Usage N
Patient Sequence Number1
Patient Age50 YR
Patient Weight68
-
-